- Home
- JL vs BLRX Comparison
JL vs BLRX Comparison
Compare JL & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JL
- BLRX
- Stock Information
- Founded
- JL 1985
- BLRX 2003
- Country
- JL Hong Kong
- BLRX Israel
- Employees
- JL N/A
- BLRX N/A
- Industry
- JL
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- JL
- BLRX Health Care
- Exchange
- JL NYSE
- BLRX Nasdaq
- Market Cap
- JL 14.8M
- BLRX 12.2M
- IPO Year
- JL 2024
- BLRX 2011
- Fundamental
- Price
- JL $3.48
- BLRX $2.94
- Analyst Decision
- JL
- BLRX Buy
- Analyst Count
- JL 0
- BLRX 2
- Target Price
- JL N/A
- BLRX $26.00
- AVG Volume (30 Days)
- JL 34.3K
- BLRX 26.6K
- Earning Date
- JL 04-08-2025
- BLRX 05-27-2025
- Dividend Yield
- JL N/A
- BLRX N/A
- EPS Growth
- JL N/A
- BLRX N/A
- EPS
- JL 0.54
- BLRX N/A
- Revenue
- JL $32,831,195.00
- BLRX $28,940,000.00
- Revenue This Year
- JL N/A
- BLRX N/A
- Revenue Next Year
- JL N/A
- BLRX N/A
- P/E Ratio
- JL $6.66
- BLRX N/A
- Revenue Growth
- JL 7.72
- BLRX 502.92
- 52 Week Low
- JL $0.23
- BLRX $2.85
- 52 Week High
- JL $13.41
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- JL 33.39
- BLRX 37.85
- Support Level
- JL $3.50
- BLRX $3.01
- Resistance Level
- JL $5.27
- BLRX $3.61
- Average True Range (ATR)
- JL 0.45
- BLRX 0.21
- MACD
- JL -0.11
- BLRX 0.01
- Stochastic Oscillator
- JL 8.17
- BLRX 11.84
About JL J-LONG GROUP LIMITED
J-Long Group Ltd is an established distributor in Hong Kong of reflective and non-reflective garment trims including, among others, heat transfers, fabrics, woven labels and tapes, sewing badges, piping, zipper pullers and drawcords. It also offers a wide range of apparel solution services to cater to its customers' needs for reflective and non-reflective garment trims, ranging from market trend analysis, product design and development and production to quality control.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.